PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study by unknown
ORIGINAL RESEARCH
PPAR-a Agonist Fenofibrate Reduces Insulin Resistance
in Impaired Glucose Tolerance Patients
with Hypertriglyceridemia: A Cross-Sectional Study
Xiaomeng Feng . Xia Gao . Yumei Jia . Yuan Xu
Received: February 7, 2017 / Published online: March 30, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Introduction: Peroxisome proliferator-acti-
vated receptor-a (PPAR-a) agonists can regulate
metabolism and protect the cardiovascular sys-
tem. This study investigated the effects of
PPAR-a agonist fenofibrate on insulin resistance
in patients with impaired glucose tolerance
(IGT).
Methods: This research evaluated cross-sec-
tional and interventional studies. 191 subjects
with IGT were divided into a hypertriglyc-
eridemia group (HTG group, n = 118) and a
normal triglyceride (TG) group (NTG group,
n = 73). 79 subjects with normal glucose toler-
ance were recruited as a control group. The HTG
group was treated with fenofibrate (200 mg/day)
for 12 weeks. The homeostatic model assess-
ment index 2 (HOMA2) and the McAuley index
(McA) were calculated.
Results: HOMA2 for b-cell function
(HOMA2-%B) was 93.47 ± 26.28, 68.47 ± 21.29,
and 79.92 ± 23.15 in HTG, NTG, and control
groups, respectively. HOMA2 for insulin sensi-
tivity (HOMA2-%S) was 48.40 (39.70, 68.70),
110.20 (62.55, 141.95), and 101.20 (79.90,
140.10) in HTG, NTG, and control groups,
respectively. HOMA2 for insulin resistance
(HOMA2-IR) was 2.09 (1.46, 2.52), 0.92 (0.70,
1.61), and 0.99 (0.71, 1.25) in HTG, NTG, and
control groups, respectively. McA was
5.05 ± 0.76, 7.99 ± 1.79, and 8.34 ± 1.55 in
HTG, NTG, and control groups, respectively.
The HTG group had higher HOMA2-%B and
HOMA2-IR, and lower HOMA2-%S and McA
than NTG and control groups (P\0.001 for all).
Fenofibrate decreased HOMA2-%B and
HOMA2-IR and increased HOMA2-%S and McA
in the HTG group (HOMA2-%B: from
93.47 ± 26.28 to 89.34 ± 23.53, P = 0.018;
HOMA2-%S: from 48.40 (39.70, 68.70) to 56.75
(44.88, 72.53), P\0.001; HOMA2-IR: from 2.07
(1.46, 2.52) to 1.76 (1.38, 2.30), P\0.001; McA:
from 5.05 ± 0.76 to 9.34 ± 0.88, P\0.001).
Conclusion: PPAR-a agonists improve parame-
ters of glucoregulation in IGT patients with
hypertriglyceridemia.
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INTRODUCTION
Impaired glucose tolerance (IGT), the major risk
factor correlated with the development of both
type 2 diabetes mellitus (T2DM) [1] and
atherosclerotic cardiovascular diseases [2], is
frequently associated with insulin resistance
which is the central feature of metabolic syn-
drome [3]. Hypertriglyceridemia is considered
as an important risk factor for insulin resistance
and islet b-cell dysfunction. Lipoprotein lipase
gene knockout heterozygous mice, an animal
model of genetic hypertriglyceridemia, present
high insulin resistance, compensatory increase
of insulin secretion, and impaired glucose tol-
erance [4], indicating that hypertriglyceridemia
could contribute to disorders of gly-
cometabolism mediated through insulin resis-
tance and b-cell dysfunction.
Fenofibrate, an important peroxisome pro-
liferator-activated receptor-a (PPAR-a) agonist,
is widely used in clinical as a triglyceride
(TG)-lowering agent [5] which is effective at
decreasing TG levels, increasing high-density
lipoprotein cholesterol (HDL-C) levels, and
changing low-density lipoprotein cholesterol
(LDL-C) particle morphology [6]. Some large-s-
cale clinical researches have shown that fenofi-
brate exerts highly beneficial effects on
protecting against cardiovascular events in
patients with T2DM apart from regulating lipid
metabolism [7]. Thus, PPAR-a agonists may
reduce cardiovascular morbidity and mortality
[8] through lipid-lowering-dependent and
lipid-lowering-independent mechanisms [7, 9].
Our previous studies demonstrated that fenofi-
brate decreased circulating irisin levels [10] and
C–C chemokine ligand 5 (CCL5) levels [11] in
T2DM patients with hypertriglyceridemia.
The insulin-sensitizing effects of fenofibrate,
which can improve glycometabolism and pro-
tect the cardiovascular system, have remained
controversial. Most studies have indicated the
insulin-sensitizing actions of fenofibrate,
although the actions have been questioned by
other studies. Some studies have demonstrated
that fenofibrate exerted protective effects on
hypertriglyceridemic patients with prediabetes
[12], and ameliorated insulin resistance in
hypertriglyceridemic patients with normal glu-
cose tolerance (NGT) [13]. On the contrary,
other studies have found that fenofibrate has no
effects on the insulin sensitivity in insulin-re-
sistant nondiabetic subjects [14] or in subjects
with T2DM [15, 16]. Thus, we aimed to examine
whether treatment with the PPAR-a agonist
fenofibrate affected insulin resistance in
patients with IGT in this study.
METHODS
Subjects
A total of 270 subjects (both genders) ranging in
age from 30 to 70 years were recruited from July
2014 to June 2016 from a group of outpatients
at the Department of Endocrinology, Beijing
Chao-Yang Hospital, Capital Medical Univer-
sity, Beijing, China. The 75 g oral glucose tol-
erance test was performed at a screening visit for
all subjects.
The subjects diagnosed with IGT, as defined
by the American Diabetes Association criteria
[17], were eligible for the study. The following
exclusion criteria for IGT subjects were applied:
normal glucose tolerance, impaired fasting glu-
cose, and diabetes. Hypertriglyceridemia was
defined by TG levels of at least 1.7 mmol/L
according to the guideline of National Choles-
terol Education Program Adult Treatment Panel
III and the Endocrine Society [18, 19]. On the
basis of TG levels, all IGT subjects were divided
into a hypertriglyceridemia group (HTG group,
n = 118) and a normal TG group (NTG group,
n = 73).
Seventy-nine subjects with NGT were
recruited as the control group. None of them
had a history of prediabetes (including impaired
glucose tolerance and impaired fasting glucose),
diabetes, or hypertriglyceridemia.
People with hypertension, coronary artery
disease, endocrine disease, systemic inflamma-
tory disease, infectious disease, cancer, chronic
kidney disease [i.e., creatinine (CR) greater than
120 lmol/L], hepatic enzymes [i.e., aspartate
aminotransferase (AST) and alanine amino-
transferase (ALT)] greater than 1.5 times the
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upper normal limits, creatine kinase (CK)
greater than 1.5 times the upper normal limit, a
history of alcohol abuse, pregnancy, and lacta-
tion were excluded. People taking agents known
to influence glucose or insulin metabolism,
and/or people being treated with lipid-lowering
drugs were also excluded.
Study Design
Subjects in the HTG group were required to
attend three study visits: the screening visit,
visit 1, and visit 2 (spaced 12 weeks apart),
while subjects in NTG and control groups
attended the screening visit. Starting at visit 1,
subjects in the HTG group who fulfilled the
inclusion criteria (without any exclusion cri-
teria) were treated with fenofibrate at
200 mg/day for 12 weeks. The drugs were
counted at visit 2, and compliance was con-
sidered to be satisfactory if more than 90% of
capsules were taken.
Blood samples and the data on the medical
history, height, weight, and blood pressure
were collected at the screening visit (all three
groups) and at visit 2 (HTG group) (under
fasting conditions, as described below). At visit
1, each subject in the HTG group received
instructions to maintain his/her usual nutri-
tional and exercise habits. Subjects in the HTG
group were asked to immediately report the
development of unusual muscle soreness or
pain throughout the study. In addition, any
adverse event in the HTG group was recorded
at visit 2.
Compliance with Ethics Guidelines
The study protocol was approved by the
Medicine and Pharmacy Ethics Committee of
Beijing Chao-Yang Hospital, Capital Medical
University. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human experi-
mentation (institutional and national) and
with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was
obtained from all patients for being included
in the study.
Data Collection and Laboratory Tests
A standard questionnaire was used to collect
information about the subjects’ health status
and medications. Height and weight were
measured without shoes and in light clothing to
the nearest 0.1 cm and 0.1 kg, respectively, by
the same trained group. Body mass index (BMI)
was calculated as weight (kg)/[height (m)]2.
Blood pressure was measured using a calibrated
standard mercury sphygmomanometer. All
readings were measured from the non-domi-
nant arm after a 5-min resting period with the
patients in the sitting position.
Fasting blood samples were collected in the
morning after an 8-h overnight fast. Total
cholesterol (TC), HDL-C, LDL-C, TG, free fatty
acids (FFA), CR, AST, ALT, CK, fasting blood
glucose (FBG), 2-h postchallenge glucose
(2hPG), glycosylated hemoglobin (HbA1c),
fasting insulin (FINS), and high sensitivity C-
reactive protein (hsCRP) were measured in the
central laboratory of Beijing Chao-Yang Hospi-
tal, Capital Medical University.
IInsulin resistance was measured with the
following surrogates: homeostatic model assess-
ment index 2 for b-cell function (HOMA2-%B, a
marker of insulin secretion), homeostatic model
assessment index 2 for insulin sensitivity
(HOMA2-%S), and homeostatic model assess-
ment index 2 for insulin resistance (HOMA2-IR)
were calculated with the homeostatic model
assessment index 2 (HOMA2) calculator version
2.2 (www.dtu.ox.ac.uk/homacalculator/index.
php). The McAuley index (McA) = exp
[2.63 - 0.28 ln FINS (mIU/L) - 0.31 ln TG
(mmol/L)].
Adverse events were recorded throughout
the study. The safety parameters included CR,
AST, ALT, and CK.
Statistical Analysis
All analyses were performed with Statistical
Package for Social Sciences version 19.0 (SPSS,
Inc., Chicago, IL, USA). The normality of data
distribution was verified using the Kol-
mogorov–Smirnov test. Normally distributed
data were expressed as the means ± standard
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deviations. Non-normally distributed data were
given as medians (25th and 75th percentiles).
Comparisons of the baseline clinical and bio-
chemical markers among three groups were
performed using one-way ANOVA and
Kruskal–Wallis H test. Comparisons of the pre-
treatment and posttreatment (with fenofibrate)
clinical and biochemical markers in HTG group
were performed with paired t test and Wilcoxon
test. Proportions were analyzed using the
Chi-squared test. The associations between
anthropometric parameters and lipid profile
and HOMA2-%B, HOMA2-%S, HOMA2-IR, or
McA were examined using Pearson’s and
Spearman’s correlation coefficient analyses.
HOMA2-%S and HOMA2-IR did not follow a
normal distribution. After logarithmic transfor-
mation, the data of HOMA2-%S and HOMA2-IR
were fitted to a normal distribution. Variables
with a P value less than 0.05 in Pearson’s and
Spearman’s correlation coefficient analyses were
retained for the multiple stepwise regression
analyses. All tests were two-sided, and a P value
less than 0.05 was used to indicate statistical
significance for the results. However, given the
multiple comparison performed, statistical sig-
nificance at the 0.017 (0.05 divided by the
number of comparisons) should be used.
RESULTS
Baseline Clinical Characteristics in Study
Subjects
The baseline clinical characteristics of the study
subjects are listed in Table 1. The subjects in the
three groups were similar in sex, age, systolic
blood pressure (SBP), diastolic blood pressure
(DBP), and TC (P[0.05 for all). A significant
trend was observed for BMI, HDL-C, LDL-C, TG,
FFA, FBG, 2hPG, HbA1c, FINS, and hsCRP
among the three groups (BMI, HDL-C, FBG,
2hPG, HbA1c, and FINS: P\0.01; LDL-C, TG,
FFA, and hsCRP: P\0.05). The HTG group had
significantly increased levels of BMI, TG, FFA,
FBG, and FINS and significantly decreased levels
of HDL-C compared with the control and NTG
groups (P\0.01 for all). The levels of FBG were
significantly elevated in the NTG group
compared to those in control group (P\0.01).
Both HTG and NTG groups exhibited signifi-
cantly higher levels of 2hPG and HbA1c than
the control group (P\0.01 for both). The HTG
group had higher levels of LDL-C and hsCRP
than the control group (P\0.017 for both).
Baseline Values of HOMA2-%B,
HOMA2-%S, HOMA2-IR, and McA in Study
Subjects
The baseline values of HOMA2-%B,
HOMA2-%S, HOMA2-IR, and McA in study
subjects are exhibited in Table 2. The baseline
values of HOMA2-%B were 93.47 ± 26.28,
68.47 ± 21.29, and 79.92 ± 23.15 in HTG, NTG,
and control groups, respectively. The baseline
values of HOMA2-%S were 48.40 (39.70, 68.70),
110.20 (62.55, 141.95), and 101.20 (79.90,
140.10) in HTG, NTG, and control groups,
respectively. The baseline values of HOMA2-IR
were 2.09 (1.46, 2.52), 0.92 (0.70, 1.61), and
0.99 (0.71, 1.25) in HTG, NTG, and control
groups, respectively. The baseline values of McA
were 5.05 ± 0.76, 7.99 ± 1.79, and 8.34 ± 1.55
in HTG, NTG, and control groups, respectively.
The values of HOMA2-%B and HOMA2-IR in
the HTG group were significantly higher than
those in the NTG and control groups (P\0.001
for all), and a significant decrease in
HOMA2-%S and McA was observed in the HTG
group compared with the NTG and control
groups (P\0.001 for all). No statistically sig-
nificant differences were observed in
HOMA2-%B, HOMA2-%S, HOMA2-IR, and McA
between NTG and control groups.
Correlation Between Anthropometric
Parameters and Lipid Profile and Values
of HOMA2-%B, HOMA2-%S, HOMA2-IR,
and McA
HOMA2-%B was positively correlated with TG
(r = 0.359, P\0.001) and BMI (r = 0.215,
P\0.001) and inversely related to HDL-C
(r = -0.198, P = 0.001) (Table 3). After adjust-
ing for the confounders, the multiple stepwise
regression analysis showed that the increased
levels of TG (b = 8.055, P\0.001) and BMI
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(b = 0.920, P = 0.011) were independently rela-
ted to high HOMA2-%B. The model had an
adjusted R2 of 0.143, F = 23.464, and P\0.001.
HOMA2-%S was negatively associated with
TG (r = -0.623, P\0.001), BMI (r = -0.314,
P\0.001), and LDL-C (r = -0.132, P = 0.030)
and positively related to HDL-C (r = 0.344,
P\0.001) (Table 3). After controlling for con-
founders, the multiple stepwise regression
analysis showed that the decreased levels of TG
(b = -0.242, P\0.001) and BMI (b = -0.020,
P = 0.001) and the increased levels of HDL-C
(b = 0.243, P = 0.002) were independently cor-
related with high HOMA2-%S. The model had
an adjusted R2 of 0.382, F = 56.485, and
P\0.001.
HOMA2-IR was positively correlated with TG
(r= 0.622, P\0.001), BMI (r= 0.306, P\0.001),
LDL-C (r= 0.136, P= 0.025), and FFA (r= 0.129,
P= 0.034) and negatively related to HDL-C
(r=-0.346, P\0.001) (Table 3). After adjusting
for the confounders, the multiple stepwise
regression analysis showed that the high levels of
TG (b= 0.241, P\0.001) and BMI (b= 0.020,
P= 0.002) and the low levels of HDL-C
(b=-0.252, P= 0.001) were independently rela-
ted to increased HOMA2-IR. The model had an
adjusted R2 of 0.380, F= 55.919, and P\0.001.








Sex (M/F) 71/47 39/34 40/39 0.382
Age (years) 56.12 ± 8.51 58.23 ± 7.14 56.68 ± 7.70 0.198
BMI (kg/m2) 26.47 ± 4.68a,b 24.78 ± 3.65 24.28 ± 3.50 0.001
SBP (mmHg) 127.51 ± 6.04 126.03 ± 6.81 126.29 ± 6.81 0.235
DBP (mmHg) 75.50 ± 6.49 74.42 ± 7.17 74.10 ± 7.45 0.335
TC (mmol/L) 5.13 ± 1.04 4.99 ± 0.95 4.87 ± 0.92 0.189
HDL-C (mmol/L) 1.34 ± 0.28a,b 1.56 ± 0.38 1.56 ± 0.35 \0.001
LDL-C (mmol/L) 3.10 ± 0.74a 2.92 ± 0.78 2.83 ± 0.77 0.041
TG (mmol/L) 2.37 (1.99, 2.81)a,b 1.18 (0.73, 1.51) 1.03 (0.69, 1.45) 0.015
FFA (mmol/L) 0.67 ± 0.18a,b 0.49 ± 0.15 0.44 ± 0.14 0.023
hsCRP (mg/L) 1.64 (1.04, 2.57)a 1.47 (0.64, 2.63) 1.15 (0.34, 2.38) 0.048
FBG (mmol/L) 6.33 ± 0.49a,b 6.06 ± 0.50a 5.49 ± 0.39 \0.001
2hPG (mmol/L) 9.34 ± 0.88a 9.31 ± 0.89a 6.34 ± 0.73 \0.001
HbA1c (%) 6.30 (6.00, 6.40)a 6.20 (6.00, 6.30)a 5.90 (5.50, 6.10) \0.001
FINS (mIU/L) 15.50 (10.78, 18.60)a,b 6.80 (5.20, 11.70) 7.53 (5.30, 9.40) 0.001
HTG group impaired glucose tolerance patients with hypertriglyceridemia, NTG group impaired glucose tolerance patients
without hypertriglyceridemia; control group, control subjects; BMI body mass index, SBP systolic blood pressure, DBP
diastolic blood pressure, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, TG triglycerides, FFA free fatty acids, hsCRP high sensitivity C-reactive protein, FBG fasting blood glucose,
2hPG 2-h postchallenge glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin
a P\0.017 (0.05 divided by the number of comparisons), signiﬁcantly different compared with control group
b P\0.017 (0.05 divided by the number of comparisons), signiﬁcantly different compared with the NTG group
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McA was inversely associated with TG
(r = -0.797, P\0.001), BMI (r = -0.341,
P\0.001), LDL-C (r = -0.295, P\0.001), and
FFA (r = -0.214, P\0.001) and positively rela-
ted to HDL-C (r = 0.424, P\0.001) (Table 3).
After adjusting for the confounders, the multi-
ple stepwise regression analysis showed that the
reduced levels of TG (b = -1.323, P\0.001),
BMI (b = -0.067, P\0.001), and LDL-C
(b = -0.256, P = 0.006) and the elevated levels








HOMA2-%B 93.47 ± 26.28a,b 68.47 ± 21.29 79.92 ± 23.15 \0.001
HOMA2-%S 48.40 (39.70, 68.70)a,b 110.20 (62.55, 141.95) 101.20 (79.90, 140.10) \0.001
HOMA2-IR 2.09 (1.46, 2.52)a,b 0.92 (0.70, 1.61) 0.99 (0.71, 1.25) \0.001
McA 5.05 ± 0.76a,b 7.99 ± 1.79 8.34 ± 1.55 \0.001
HTG group impaired glucose tolerance patients with hypertriglyceridemia, NTG group impaired glucose tolerance patients
without hypertriglyceridemia; control group, control subjects; HOMA2-%B homeostasis model assessment index 2 for b-cell
function, HOMA2-%S, homeostasis model assessment index 2 for insulin sensitivity, HOMA2-IR homeostasis model
assessment index 2 for insulin resistance, McA McAuley index
a P\0.017 (0.05 divided by the number of comparisons), signiﬁcantly different compared with control group
b P\0.017 (0.05 divided by the number of comparisons), signiﬁcantly different compared with the NTG group
Table 3 Correlation between the anthropometric parameters and lipid proﬁle associated with HOMA2-%B, HOMA2-%S,
HOMA2-IR, or McA
Parameters HOMA2-%B (n5 270) HOMA2-%S (n5 270) HOMA2-IR (n5 270) McA (n 5 270)
r P value r P value r P value r P value
Age (years) -0.092 0.131 0.080 0.189 -0.088 0.150 0.089 0.146
BMI (kg/m2) 0.215 \0.001 -0.314 \0.001 0.306 \0.001 -0.341 \0.001
SBP (mmHg) 0.060 0.326 -0.119 0.052 0.110 0.067 -0.080 0.193
DBP (mmHg) -0.038 0.530 -0.057 0.348 0.067 0.271 -0.040 0.516
TC (mmol/L) 0.010 0.872 -0.031 0.606 0.038 0.536 -0.108 0.074
HDL (mmol/L) -0.198 0.001 0.344 \0.001 -0.346 \0.001 0.424 \0.001
LDL (mmol/L) 0.036 0.551 -0.132 0.030 0.136 0.025 -0.295 \0.001
TG (mmol/L) 0.359 \0.001 -0.623 \0.001 0.622 \0.001 -0.797 \0.001
FFA (mmol/L) 0.093 0.123 -0.120 0.051 0.129 0.034 -0.214 0.001
hsCRP (mg/L) 0.063 0.300 -0.029 0.632 0.031 0.613 -0.003 0.965
HOMA2-%B homeostasis model assessment index 2 for b-cell function, HOMA2-%S homeostasis model assessment index 2
for insulin sensitivity, HOMA2-IR homeostasis model assessment index 2 for insulin resistance, McA McAuley index, BMI
body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, FFA free fatty acids, hsCRP high
sensitivity C-reactive protein
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of HDL-C (b = 1.107, P\0.001) were indepen-
dently related to increased McA. The model had
an adjusted R2 of 0.701, F = 158.586, and
P\0.001.
Effects of Fenofibrate on Clinical
Characteristics in HTG Group
The pretreatment and posttreatment (with
fenofibrate) clinical parameters in the HTG
group are summarized in Table 4. No statisti-
cally significant changes were observed in BMI,
SBP, DBP, AST, ALT, CK, FBG, 2hPG, and HbA1c
after 12 weeks of fenofibrate treatment com-
pared with the baseline in HTG group (P[0.05
for all). Compared with the baseline, at visit 2,
the patients in the HTG group presented sig-
nificantly lower levels of TC, LDL-C, TG, FFA,
FINS, and hsCRP (P\0.01 for all), but signifi-
cantly higher levels of HDL-C and CR (P\0.01
for both).
Effects of Fenofibrate on HOMA2-%B,
HOMA2-%S, HOMA2-IR, and McA in HTG
Group
Fenofibrate treatment significantly decreased
the values of HOMA2-%B and HOMA2-IR and
increased the values of HOMA2-%S and McA
after 12 weeks compared with the baseline in






BMI (kg/m2) 26.47 ± 4.68 26.43 ± 4.59 0.176
SBP (mmHg) 127.51 ± 6.04 127.94 ± 6.58 0.158
DBP (mmHg) 75.50 ± 6.49 75.59 ± 6.53 0.806
TC (mmol/L) 5.13 ± 1.04 4.85 ± 0.86 0.001
HDL-C (mmol/L) 1.34 ± 0.28 1.44 ± 0.33 \0.001
LDL-C (mmol/L) 3.10 ± 0.74 2.91 ± 0.67 0.003
TG (mmol/L) 2.37 (1.99, 2.81) 1.62 (1.16, 1.97) \0.001
FFA (mmol/L) 0.67 ± 0.18 0.45 ± 0.16 \0.001
hsCRP (mg/L) 1.64 (1.04, 2.57) 1.28 (0.53, 2.05) 0.004
CR (lmol/L) 67.56 ± 17.26 72.03 ± 16.42 0.001
AST (IU/L) 21.00 (17.00, 24.00) 20.00 (18.00, 25.00) 0.446
ALT (IU/L) 22.00 (18.75, 28.00) 22.00 (17.00, 28.00) 0.351
CK (IU/L) 84.00 (66.00, 114.50) 78.00 (63.00, 111.50) 0.911
FBG (mmol/L) 6.33 ± 0.49 6.27 ± 0.49 0.123
2hPG (mmol/L) 9.34 ± 0.88 9.18 ± 0.74 0.092
HbA1c (%) 6.30 (6.00, 6.40) 6.30 (6.00, 6.40) 0.777
FINS (mIU/L) 15.50 (10.78, 18.60) 13.10 (9.90, 16.43) \0.001
IGT impaired glucose tolerance, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total
cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, FFA
free fatty acids, hsCRP high sensitivity C-reactive protein, CR creatinine, AST aspartate aminotransferase, ALT alanine
aminotransferase, CK creatine kinase, FBG fasting blood glucose, 2hPG 2-h postchallenge glucose, HbA1c glycosylated
hemoglobin, FINS fasting insulin
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HTG group (HOMA2-%B: from 93.47 ± 26.28 at
pretreatment to 89.34 ± 23.53 at posttreatment,
P = 0.018; HOMA2-%S: from 48.40 (39.70,
68.70) at pretreatment to 56.75 (44.88, 72.53) at
posttreatment, P\0.001; HOMA2-IR: from 2.07
(1.46, 2.52) at pretreatment to 1.76 (1.38, 2.30)
at posttreatment, P\0.001; McA: from
5.05 ± 0.76 at pretreatment to 9.34 ± 0.88 at
posttreatment, P\0.001) (Table 5).
Correlation Between Change in TG
and Change in HOMA2-%B, HOMA2-%S,
HOMA2-IR, or McA
No statistically significant correlation was
observed between the change in TG and the
change in HOMA2-%B, HOMA2-%S, or
HOMA2-IR. However, the change in TG were
inversely related to the change in McA
(r = -0.768, P\0.001).
DISCUSSION
In the present study, the HTG group exhibited
significantly higher values of FINS, HOMA2-%B,
and HOMA2-IR and significantly lower values of
HOMA2-%S and McA compared with the control
and NTG groups. The increased levels of TG and
BMI were independently related to high
HOMA2-%B; the decreased levels of TG and BMI
and the increased levels of HDL-C were indepen-
dently correlated with increased HOMA2-%S; the
high levels of TG and BMI and the low levels of
HDL-C were independently related to increased
HOMA2-IR; and the reduced levels of TG, BMI,
and LDL-C and the increased levels of HDL-C
were independently associated with high McA.
Importantly, fenofibrate treatment administered
to the IGT patients with hypertriglyceridemia for
12 weeks resulted in the significant decrease in
FINS, HOMA2-%B, and HOMA2-IR and the sig-
nificant increase in HOMA2-%S and McA; the
change in TG was inversely related to the change
in McA. Our findings are similar to the previous
studies in hypertriglyceridemic patients with
prediabetes [12] or with NGT [13]. However, our
findings are in contrast to some recent studies in
nondiabetic individuals with insulin resistance
[14] or in subjects with T2DM [15, 16]. It is pos-
sible that these conflicting data are caused by the
poly-pharmacotherapy and other confounding
variables of the study populations.
Although there are some studies linking dia-
betes to defects in beta cell mass and insulin
secretion [20], most studies have supported that a
compensatory period (i.e., a compensatory
increase in insulin production that is secondary to
high insulin resistance and the elevated secreting
load of islet b-cells with subtle changes in glucose
levels) has been identified before diabetes, and
insulin production decreases after the diagnosis of
diabetes [21]. Insulin resistance might be consid-
ered to be responsible for the increase in the
secreting load of islet b-cells and insulin secretion
during the compensatory period. HOMA2-%B
reflects insulin secretion rather than b-cell
‘‘health’’ [22]. Hence, the decrease of HOMA2-%B
and HOMA2-IR and the increase of HOMA2-%S
and McA after 12 weeks of fenofibrate therapy in







HOMA2-%B 93.47 ± 26.28 89.34 ± 23.53 0.018
HOMA2-%S 48.40 (39.70, 68.70) 56.75 (44.88, 72.53) \0.001
HOMA2-IR 2.07 (1.46, 2.52) 1.76 (1.38, 2.30) \0.001
McA 5.05 ± 0.76 9.34 ± 0.88 \0.001
IGT impaired glucose tolerance, HOMA2-%B homeostasis model assessment index 2 for b-cell function, HOMA2-%S
homeostasis model assessment index 2 for insulin sensitivity, HOMA2-IR homeostasis model assessment index 2 for insulin
resistance, McA McAuley index
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our study indicated the reduction of the secreting
load of b-cells and insulin secretion, with the
decreased insulin resistance, through fenofibrate
treatment. However, the exact mechanism
involved in these effects of fenofibrate has not
been fully elucidated.
Evidence accumulated has shown that
hypertriglyceridemia causes an excess of FFA,
which could increase insulin resistance and the
secreting load of b-cells [23], with ‘‘lipotoxicity’’
that is an important pathogenetic factor
directly associated with peripheral tissue insulin
resistance and islet b-cell dysfunction [24]. On
the other hand, hyperinsulinemia increases
triglycerides and closes the vicious circle even-
tually [25]. When insulin secretion is insuffi-
cient and blood glucose levels rise, prediabetes
become overt. Therefore, insulin resistance and
b-cell dysfunction might be the result of
chronic exposure to hypertriglyceridemia [26].
PPAR-a agonists might increase insulin sensi-
tivity and protect b-cell function through
decreasing hypertriglyceridemia. PPAR-a ago-
nists significantly attenuate muscle TG, total
liver TG content, and visceral fat weight [27],
indicating that PPAR-a agonists ameliorate
insulin resistance and the secreting load of islet
b-cells through reducing ectopic lipid storage.
In addition, PPAR-a agonists reduce the levels of
FFA [28], especially when TG levels are mark-
edly increased [9], which has been identified by
our study. Therefore, PPAR-a agonists could
promote insulin sensitivity in IGT patients with
hypertriglyceridemia through inhibiting
‘‘lipotoxicity’’.
Additionally, HDL-C, an anti-atherogenic
lipoprotein, decreases insulin resistance and
b-cell dysfunction. HDL-C may activate the
phosphorylation of adenosine 50-monophos-
phate-activated protein kinase to induce glu-
cose uptake [29]. Moreover, HDL-C removes
cholesterol from b-cells, which regulates islet
b-cell function [30]. Low HDL-C has been doc-
umented to promote the progression of diabetes
[31]. In our study, the fenofibrate treatment
significantly increased HDL-C levels, which
might exert favorable effects on alleviating
insulin resistance and b-cell dysfunction.
Furthermore, our finding that BMI is posi-
tively related to HOMA2-%B and HOMA2-IR
and negatively associated with HOMA2-%S and
McA is consistent with the previous study
showing that a reduction in BMI was associated
with a decrease in HOMA-b and an improve-
ment in insulin sensitivity in obese individuals
[32]. Thus, the reduction of BMI may lead to
improving b-cell function, reducing insulin
resistance, and decreasing the needs for com-
pensatory hyperinsulinemia. PPAR-a agonists
have been reported to elicit brown adipocytes
and to induce weight loss in diet-induced obese
mice [33], which might cause the protection of
insulin sensitivity and islet b-cell function.
However, no significant change was observed in
BMI after 12 weeks of fenofibrate treatment
compared with the baseline in the HTG group
in our study, since observation time might not
be long enough.
Recent evidence has also suggested that
inflammation might be crucial for the devel-
opment of insulin resistance and b-cell dys-
function [34]. Inflammatory cytokines and
acute-phase reactants are positively related to
insulin resistance in patients with metabolic
syndrome [35]. It has been reported that PPAR-a
agonists have anti-inflammatory effects [36]. In
our previous study, PPAR-a agonist fenofibrate
suppressed the levels of hsCRP and CCL5 in
T2DM patients with hypertriglyceridemia [11].
In the present study, fenofibrate also reduced
the levels of hsCRP in IGT patients with
hypertriglyceridemia. It is possible that PPAR-a
agonists prevent insulin resistance and b-cell
dysfunction through anti-inflammation.
On the basis of previous research, insulin
resistance is involved in the increasing risk of
cardiovascular events [37]. Therefore, our pre-
sent results indicated that the HTG group, with
higher HOMA2-%B and HOMA2-IR and lower
HOMA2-%S and McA, was at higher risk for the
progression of cardiovascular diseases not only
than the control group but also the NTG group.
Furthermore, our findings that treatment with
the PPAR-a agonist fenofibrate decreased
HOMA2-%B and HOMA2-IR and increased
HOMA2-%S and McA in the IGT patients with
hypertriglyceridemia may partially explain the
beneficial effects of PPAR-a agonist treatment in
clinical trials in which the favorable effects only
partly correlated with lipid changes [7]. Our
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results support that PPAR-a agonists may pro-
tect against the cardiovascular complications of
prediabetes and diabetes, at least in part,
through improving insulin sensitivity and b-cell
function, although further animal and clinical
studies are still needed to investigate the
mechanism.
The limitations of our study are identified as
follows. Firstly, our study population was limited
to Chinese subjects. Therefore, our findings may
not be directly applicable to other populations.
Secondly, our sample size was relatively small so
that our findings were not powerful enough to
account for potentially confounding factors in
our analyses, and our results could be improperly
influenced by some outliers as a result of the
sample size. Thirdly, our study was not a ran-
domized controlled trial. Considering ethics
guidelines, we chose a self-control study and
compared pretreatment and posttreatment (with
fenofibrate) parameters in the HTG group. How-
ever, it might introduce some bias. Fourthly, our
study estimated insulin resistance by HOMA2 and
McA. Although the updated HOMA2 model
accounts for variations in hepatic and peripheral
glucose resistance, allows for an increase in insu-
lin secretion in response to a plasma glucose
concentration of greater than 10 mmol/L, incor-
porates an estimate of proinsulin secretion into
the model and thus allows the use of either total
[radioimmunoassay (RIA)] or specific insulin
assays, and includes renal glucose losses in
hyperglycemic subjects [22], and some studies
have shown that the log-transformed values for
fasting insulin and fasting triglycerides are accu-
rate predictors of insulin sensitivity in the general
population [38], they are still surrogates of the
precise methods such as the hyperglycemic and
hyperinsulinemic clamp technique. Finally, one
should acknowledge that long-term follow-up
will be necessary to evaluate whether fenofibrate
delays disease progression eventually.
CONCLUSION
We report the significant increases in HOMA2-%B
and HOMA2-IR and the significant decreases in
HOMA2-%S and McA in the IGT patients with
hypertriglyceridemia. More importantly, we
present data that fenofibrate treatment signifi-
cantly reduced HOMA2-%B and HOMA2-IR and
elevated HOMA2-%S andMcA in the IGT patients
with hypertriglyceridemia. These results indicate
that PPAR-a agonists might improve parameters
of glucoregulation in IGT patients with
hypertriglyceridemia.
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